IgE-mediated anaphylactic reaction to purified and recombinant factor VIII in a patient with severe haemophilia A.
We report a 51-year-old patient with severe haemophilia A developing a severe life-threatening anaphylactic reaction to recombinant factor VIII (rFVIII). Anaphylactic reactions are a rare but well-known side effect of FVIII products. The nature of these reactions could not be clarified as previous studies failed to demonstrate a specific IgE response. Here, we could prove a grade 3 anaphlyactic reaction as an IgE-mediated response to rFVIII for the first time by Western blotting.
Kadar
J G
JG
Outpatient-Clinic and Laboratory for Transfusion Medicine, University of Colognem Köln, Germany.
Schuster
J
J
Hunzelmann
N
N
D000707:Anaphylaxis / Q000276:immunology*; D015153:Blotting, Western / Q000379:methods; D003029:Coagulants / Q000009:adverse effects* / Q000627:therapeutic use; D005169:Factor VIII / Q000009:adverse effects* / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood*; D007074:Immunoglobulin G / Q000276:immunology; D007518:Isoantibodies / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012882:Skin Tests
D003029:Coagulants; D007074:Immunoglobulin G; D007518:Isoantibodies; D007073:Immunoglobulin E; C078147:F8 protein, human; D005169:Factor VIII